Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 3,110,000 shares, a decline of 11.4% from the June 30th total of 3,510,000 shares. Based on an average daily volume of 589,600 shares, the days-to-cover ratio is currently […]
Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating)’s stock price dropped 5.2% during trading on Wednesday . The stock traded as low as $21.99 and last traded at $22.06. Approximately 128,644 shares were traded during trading, a decline of 73% from the average daily volume of 480,035 shares. The stock had previously closed at $23.26. […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) shares traded up 7.5% on Friday after Bank of America raised their price target on the stock from $28.00 to $33.00. The stock traded as high as $21.29 and last traded at $20.99. 73,528 shares were traded during trading, a decline of 85% from the average session […]